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Langerhans Cell Histiocytosis (LCH) is a neoplastic disorder of hematopoietic origin
characterized by inflammatory lesions containing clonal histiocytes (LCH-cells) intermixed
with various immune cells, including T cells. In 50–60% of LCH-patients, the somatic
BRAFV600E driver mutation, which is common in many cancers, is detected in these
LCH-cells in an otherwise quiet genomic landscape. Non-synonymous mutations like
BRAFV600E can be a source of neoantigens capable of eliciting effective antitumor
CD8+ T cell responses. This requires neopeptides to be stably presented by Human
Leukocyte Antigen (HLA) class I molecules and sufficient numbers of CD8+ T cells at
tumor sites. Here, we demonstrate substantial heterogeneity in CD8+ T cell density in
n = 101 LCH-lesions, with BRAFV600E mutated lesions displaying significantly lower
CD8+ T cell:CD1a+ LCH-cell ratios (p = 0.01) than BRAF wildtype lesions. Because
LCH-lesional CD8+ T cell density had no significant impact on event-free survival, we
investigated whether the intracellularly expressed BRAFV600E protein is degraded into
neopeptides that are naturally processed and presented by cell surface HLA class I
molecules. Epitope prediction tools revealed a single HLA class I binding BRAFV600E
derived neopeptide (KIGDFGLATEK), which indeed displayed strong to intermediate
binding capacity to HLA-A∗03:01 and HLA-A∗11:01 in an in vitro peptide-HLA binding
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assay. Mass spectrometry-based targeted peptidomics was used to investigate the
presence of this neopeptide in HLA class I presented peptides isolated from several
BRAFV600E expressing cell lines with various HLA genotypes. While the HLA-A∗02:01
binding BRAF wildtype peptide KIGDFGLATV was traced in peptides isolated from all
five cell lines expressing this HLA subtype, KIGDFGLATEK was not detected in the
HLA class I peptidomes of two distinct BRAFV600E transduced cell lines with confirmed
expression of HLA-A∗03:01 or HLA-A∗11:01. These data indicate that the in silico
predicted HLA class I binding and proteasome-generated neopeptides derived from the
BRAFV600E protein are not presented by HLA class I molecules. Given that theBRAFV600E
mutation is highly prevalent in chemotherapy refractory LCH-patients who may qualify
for immunotherapy, this study therefore questions the efficacy of immune checkpoint
inhibitor therapy in LCH.
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INTRODUCTION
Langerhans Cell Histiocytosis (LCH) is a rare neoplastic disorder
of hematopoietic origin that primarily affects children, but also
involves adults (1). Its clinical manifestation varies from a single
bone lesion or benign skin rash to a widely disseminated and life-
threatening condition, similar to acute myeloid leukemia (2). The
histopathological hallmark of LCH are phenotypically aberrant
CD1a+ CD207+ histiocytes (LCH-cells), although not all
pathological CD1a+ histiocytes co-express CD207 (3). Typically,
these LCH-cells are accompanied by a diverse inflammatory
infiltrate, often including T cells (2). These T cells have been
shown to frequently make intimate contact with LCH-cells (4, 5).
While patients with high CD8+ T cell density in the tumor
infiltrate have a more favorable prognosis across many other
neoplastic diseases (6), little is still known about the presence and
clinical impact of CD8+ T cells in LCH-lesions (7–9).
Naive (CD8+) T cells require antigen binding by their T
cell receptor and co-stimulatory signals for (proper) activation.
Previous studies have already demonstrated that LCH-cells
express the co-stimulatory receptors CD40 (10–12), CD80 (3, 11–
13), ICOS ligand (ICOSL) (14) and, although variably, CD86
(3, 11, 12) in situ. Moreover, transcriptome analyses revealed
that LCH-cells express similar levels of CD40, CD80, and CD86
messenger RNA when compared to normal epidermal CD207+
Langerhans cells (15, 16), and that they confer high expression
of genes relevant for antigen presentation (including CD1E) and
genes encoding members of the HLA (class II) complex (17).
Thus, LCH-cells do not appear to have an intrinsic defect in their
capacity to elicit a T cell immune response (12). This may explain
why a proportion of LCH-lesional T cells have been shown to
express cell surface markers indicative of recent activation (2),
including CD40L (10), ICOS (14), CXCR3 (7), CD25 (5, 14),
PD-1 (18, 19), RANKL (20), and CD45RO (7). In addition,
marked monoclonal expansion of LCH-lesion infiltrating CD3+
T cells has been observed (19), suggesting that T cell receptor
activation occurred in situ. The antigen-specificity of activated
LCH-lesional T cells is, however, unknown (2).
In 2010, universal activation of the mitogen-activated
protein kinase (MAPK) signaling pathway in LCH-cells was
demonstrated (21, 22). Since then, recurrent somatic mutations
in genes of the MAPK signaling pathway have been identified
in ∼85% of LCH-patients (23, 24). Oncogenic driver mutations
are essential for tumorigenesis and tend to be clonally conserved.
This makes neoantigens derived from proteins encoded by
oncogenes highly attractive targets for immunotherapy. In
addition, the natural T cell pool should contain T cells
expressing high affinity T cell receptors for these neoantigens
(25), which may exert potent antitumor function (26–29).
This requires, however, neoantigens to be stably presented
by Human Leukocyte Antigen (HLA) class I molecules and
sufficient numbers of CD8+ T cells at tumor sites. Over the
past years, several HLA class I presented “public” neoantigens
resulting from recurrent hotspot mutations in driver oncogenes
have been discovered (30–38). Approximately 50–60% of LCH-
patients carry the somatic BRAFV600E driver mutation (1, 21).
CD8+ T cells specific for BRAFV600E derived neopeptides have
already been reported in vitro and in murine models (39–
42). Thus, activation of LCH-lesional BRAFV600E neoantigen-
specific CD8+ T cells could hypothetically lead to the
eradication of BRAFV600E expressing LCH-cells. Moreover, the
concurrent formation of long-lasting bone-marrow homing
memory CD8+ T cells could control new outgrowth of
residual BRAFV600E mutated histiocyte precursor cells (43).
Immunotherapy specifically aimed at enhancing the number
and effector function of these BRAFV600E-specific CD8+ T
cells could offer great promise in the treatment of high-
risk LCH-patients, given that these patients often bear the
BRAFV600E mutation and fail first-line chemotherapy (44).
Importantly, the BRAF gene is mutated in ∼7% of human
cancers, with the BRAFV600E mutation accounting for >90%
of all genetic variations (45, 46). Hence, the identification of
HLA class I presented “public” neoantigens derived from the
BRAFV600E protein would offer great therapeutic opportunity
for many patients with other BRAFV600E mutated neoplasms as
well (47).
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The aim of this study was therefore to (i) assess the presence
and clinical impact of lesional CD8+ T cells in (HLA and
BRAFV600E) genotyped LCH-patients, and (ii) to investigate
whether BRAFV600E derived neopeptides are presented by HLA
class I molecules and could be recognized by such CD8+ T cells.
MATERIALS AND METHODS
Patients and Samples
Patient accrual started after approval of the study protocol
(CCMO NL33428.058.10) by each local Institutional Review
Board. Only patients of whom formalin-fixed-paraffin-embedded
(FFPE) first disease onset (FDO) LCH tissue biopsies were
available were asked to participate in the study. Informed consent
was provided by n = 135 patients and/or their parents/legal
guardians. LCH diagnosis was confirmed by a combination of
clinical findings and the presence of phenotypically aberrant
CD1a+ histiocytes in the tissue biopsy. The tissue samples were
handled according to the code of conduct for proper secondary
use of human tissue of the Federation of Dutch Medical
Scientific Societies (FEDERA). Clinical information was collected
by each participating center separately using a standardized
Case Report Form (CRF) and anonymized data were provided
to the researchers of the LUMC. Events were defined as LCH
disease progression or reactivation. Progression was defined as (i)
progression of existing lesions requiring start or intensification
of systemic chemotherapy and/or radiotherapy, or (ii) the
development of new lesions when Non-Active Disease (NAD)
state had not yet been attained. LCH reactivation was defined as
the development of new lesions after NAD had been attained for
LCH FDO.
Flow Cytometric Analysis of LCH Tissue
Biopsies
Fresh LCH tissue was dissociated using a gentle MACS tissue
dissociator (Miltenyi Biotec) and single cells were cryopreserved
in DMSO and albumin containing Roswell Park Memorial
Institute (RPMI) culture medium. Before flow cytometric
analysis, cells were thawed in RPMI + 20% fetal calf serum
(FCS) + Penicillin-Streptomycin (P/S) containing 1,600 IU/ml
DNAase (Sigma-Aldrich). After washing, the cells were stained
with a mixture of different antibodies: CD45 (2D1, 1:50,
BD Biosciences), CD1a (HI149, 1:50, BD Biosciences), CD207
(DCGM4, 1:25, Beckman Coulter), CD14 (MØP9, 1:20, BD
Biosciences), CD3 (UCHT1, 1:200, BD Biosciences), CD8 (SK1,
1:100, BD Biosciences), HLA-DR (G46-6, 1:200, BD Biosciences),
and panHLA class I (G46-2.6, 1:40, BD Biosciences). The cells
were then re-washed and immediately analyzed on a FACS
ARIA3 or FACS Fusion cell sorter (BD Biosciences).
HLA Genotyping and Analysis
High-resolution HLA genotyping was performed by DKMS Life
Sciences Lab on DNA extracted from buccal swabs obtained
from n = 104 LCH-patients using an ampliqon sequencing-
based approach, as previously described (48, 49). For n = 14
additional patients, low-resolution HLA genotype data were
acquired using a sequence specific oligoprimer-based approach
(50). Hardy-Weinberg Equilibrium testing and HLA association
analyses were performed using the HLA genotype data of
Dutch LCH-patients. To evaluate statistical significance, two-
sided Fisher’s exact tests were carried out. The p-values were
corrected for multiple comparisons conform the Šidák method
(51). Odds ratios and corresponding 95% confidence intervals
were calculated according to the method of Woolf with the
Haldane correction (52, 53). Since a large control group could
lead to significant differences that are clinically irrelevant, p-
values were standardized to a smaller control sample size
following the method of Good (54). The smaller control sample
size was obtained using the following calculation: the total
number of LCH-patients plus 3 times the number of patients as
maximum allowed size for the control group.
Immunohistochemical Staining of LCH
Tissue Sections
FFPE tissue sections (4–10µm) were deposited on SuperfrostTM
(Thermo Fisher Scientific) glass slides, dried overnight at
37◦C and stored at 4◦C. Prior to immunohistochemical (IHC)
staining, selected 4µm slides were preheated at 66◦C for 1 h
and deparaffinized in xylol. For enzymatic CD1a IHC staining,
endogenous peroxidase was blocked using Methanol/0.3% H2O2
for 20min, before slides were rehydrated in ethanol and
demineralized in water baths. Antigen retrieval was performed
in boiling citrate buffer (pH 6.0) for 10min and sections
were incubated overnight with mouse IgG1-anti-human CD1a
antibody (Clone 010, 1:800, DAKO) diluted in phosphate
buffered saline (PBS)/0.5% bovine serum albumin (BSA). The
next day, Envision+ System-HRP labeled polymer anti-mouse
(DAKO) was applied for 30min and color development was
attained using commercial DAB+ (DAKO) for 10min in the
dark. This reaction was stopped using demineralized water and
slides were counterstained with Mayer’s hematoxylin (Klinipath)
for 5 s prior to mounting with Pertex (Leica Microsystems).
An earlier published protocol was used for triple
CD1a/CD3/CD8 fluorescent IHC staining (14). In brief,
antigen retrieval was performed in boiling EDTA buffer
(pH 8.0) for 10min followed by a blocking step using 10%
Normal Goat Serum in PBS/0.5% BSA for 15min at room
temperature. Slides were incubated overnight with the following
primary antibody mix: rabbit IgG-anti-human CD3 (polyclonal,
1:300, DAKO), mouse IgG2b-anti-human CD8 (clone 4B11,
1:100, Novocastra, via Leica Microsystems), and mouse
IgG1-anti-human CD1a (Clone 010, 1:400, DAKO). The
next day, tissue slides were incubated for 30min in the dark
with 1:300 diluted goat-anti-mouse IgG1 Alexa Fluor 488,
goat-anti-mouse IgG2b Alexa Fluor 546 and goat-anti-mouse
IgG2a Alexa Fluor 647 antibodies (all from Invitrogen, via
Thermofisher Life Technologies Europe). After washing in
PBS, the sections were mounted with Mowiol (homemade) or
Prolong Gold (Thermo Fisher Scientific) and stored in the dark
at 4◦C.
BRAFV600E Mutation Analysis
CD1a+ enriched tissue parts were marked by a blinded
pathologist on enzymatically CD1a stained LCH tissue slides.
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Based on these reference slides, CD1a+ enriched tissue parts
were manually microdissected from multiple consecutively
cut 10µm tissue sections prepared from the remainder of
the LCH tissue blocks. Total nucleic acid was automatically
isolated from microdissected tissue using the Siemens Tissue
Preparation System (Siemens Healthcare) robot (55). Presence of
the BRAFV600E mutation was assessed by allele-specific real-time
qPCR, as previously described (56). Of the n = 54 BRAFV600E
negative samples, absence of the BRAFV600E mutation was
confirmed in 46 samples (85%) by next-generation sequencing
(n = 39), whole exome sequencing (n = 1) (57) or BRAFV600E
droplet digital PCR (n= 6).
Quantification of T Cell Density in
LCH-Lesions
For the manual cell counting method, multiple representative
images were taken of each tissue slide at 400× magnification
using a conventional Leica DM5500 fluorescent microscope
equipped with LAS AF software (Leica Microsystems).
Images were solely taken of representative areas containing
phenotypically aberrant CD1a+ LCH-cells. Using Image J
software (version 1.47v) with the public Cell Counter plugin,
fluorescently stained CD1a+, CD3+CD8− and CD3+CD8+
cells were manually counted in all images by two independent
researchers (PGK and ECS) who were unaware of patient identity
and outcome data. The cell counts of the individual images were
added to form total CD1a+, CD3+CD8− and CD3+CD8+ cell
counts. When total cell counts differed more than 10% between
the two researchers, a third researcher (AGSH) reviewed the
cell counting results and selected the most appropriate scoring
(19/101 cases). Total CD3+ cell counts were obtained by adding
total CD3+CD8− and CD3+CD8+ cell counts. To adjust for
substantial differences in biopsy size between different patients,
which may lead to profound disparities in absolute numbers of
counted cells, ratios between the final numbers of total CD3+
and CD3+CD8+ T cells and CD1a+ LCH-cells were calculated
for each patient.
For the manual semi-quantitative eyeball estimation method,
whole slide images were taken of the same immunostained tissue
slides at 400× magnification using a Pannoramic 250 Flash II
slidescanner (3DHISTECH). These images were scored semi-
quantitatively for LCH-lesional CD3+ and CD3+CD8+ T cell
density as has been previously described (58, 59): 1+, no, or
sporadic T cells; 2+, moderate number of T cells; 3+, abundant
occurrence of T cells; and 4+, highly abundant occurrence of T
cells. Scoring examples are shown in Figure S1. Unfortunately,
n = 21/101 (21%) of the tissue slides could not be reanalyzed
due to considerable photobleaching of the fluorophores, induced
by the earlier collection of high-power images for the manual
cell counting analysis. Slides were scored independently by three
researchers (PGK, ECS and AGSH). When scorings between two
or more researchers differed more than 1 value (15/80 cases), the
scoring was reviewed by all three researchers collectively and a
consensus score was attained. Otherwise, the average score of the
three scorings determined the final result, rounded to the nearest
whole value (1–4+).
Whole slide images of sufficient quality (without significant
color casts and/or folded tissue parts that are highly
autofluorescent and/or out of focus) from n = 48 LCH-
patients were analyzed using a quantitative automated digital
image analysis method (Figure S2). First, the LCH-lesion and its
directly adjacent T cells were encircled in the whole slide image in
CaseViewer software and exported. In this way, cells that clearly
did not belong to the microenvironment of the CD1a+ LCH-cells
were excluded. Using a custom in-house developed macro in
ImageJ software, a white balance was then set for each individual
exported image by designating background, foreground and
autofluorescence. Next, uniform color thresholds for green
(CD1a+), red (CD3+CD8−), and purple (CD3+CD8+) were
applied to all images, so that only green, red, and purple areas
with color intensities higher than the threshold remained. Since
automated quantification of individual cells was not feasible, the
cumulative area of the remaining green, red, and purple areas
was measured for each image, representing the total quantity
of CD1a+, CD3+CD8−, and CD3+CD8+ cells. Purple and Red
(CD3+) area/Green (CD1a+) area and Purple (CD3+CD8+)
area/Green (CD1a+) area ratios could then be calculated for
each patient. Comparison of the results obtained using our
three separate analysis methods showed substantial concordance
(Figure S3), supporting the validity of the findings in this study.
In vitro Peptide-HLA Class I Binding
Analysis
Competition-based peptide-HLA class I binding assays were
performed as previously described (60). The HLA binding
affinities of the target peptides and strong binding reference
peptides are expressed as the concentration that inhibits 50%
binding of a fluorescently-labeled standard peptide (IC50). The
standard peptides were FLPSDCFPSV for HLA-A∗02:01 and
KVFPCALINK for HLA-A∗03:01 and HLA-A∗11:01. Notably,
the ratio between the IC50 of a target peptide and the IC50 of
an established strong binding reference peptide (for example
260:250 vs. 100:5) provides superior information on the trueHLA
class I binding capacity of the target peptide than the absolute
IC50 of the target peptide.
Generation of BRAFV600E Expressing
EBV-LCLs
The full length BRAFV600E sequence incorporated in a pBABE-
Puro-BRAF-V600E plasmid was re-cloned into a LZRS-ires-
Green Fluorescent Protein (GFP) retroviral vector by introducing
the SwaI restriction site and a kozak sequence in front of the ATG
start codon at the 5′end of the BRAFV600E sequence using Phusio
DNA polymerase. In addition, a stop codon and NotI restriction
site was introduced at the 3′end of the BRAFV600E sequence.
The original pBABE-Puro-BRAF-V600E plasmid was kindly
provided by William Hahn (Addgene plasmid #15269; http://
n2t.net/addgene:15269; RRID:Addgene_15269) (61). Ligation
of the BRAF PCR product in the LZRS vector digested
with SwaI and NotI was performed overnight at 16◦C. Prior
to spin inoculation of Phoenix packaging cells, the correct
sequence of the re-cloned BRAFV600E gene was confirmed by
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Sanger sequencing (data not shown). Retrovirus containing
supernatant was subsequently used to transduce Epstein-Barr
virus-immortalized B cell lines (EBV-LCLs) with either a control
empty LZRS vector (mock transduced EBV-LCL) or with the
new BRAFV600E containing LZRS vector (BRAFV600E transduced
EBV-LCL). Stably transduced GFPhigh cells were purified using
an ARIA3 flow cytometer prior to bulk expansion in RPMI
medium containing 10% bovine serum.
Mass Spectrometry-Based Targeted
Peptidomics
Cells were lysed at a concentration of 100e6 cells/ml lysis
buffer [50mM Tris-Cl pH 8.0, 150mM NaCl, 5mM EDTA,
0.5% Zwittergent 3–12 (N-dodecyl-N,N-dimethyl-3-ammonio-
1-propanesulfonate) and protease inhibitor (Complete, Roche
Applied Science)] for 2 h at 0◦C (62). Lysates were successively
centrifuged for 10min at 2,500 × g and for 45min at 31,000
× g to remove nuclei and other insoluble material, respectively.
Next, lysates were cleared through a CL-4B Sepharose column (1
ml/1e9 cells) and passed through an anti-panHLA class I column
containing 2.5mg W6/32 IgG per ml protein A Sepharose (62).
TheW6/32 columnwas washed three times each with 1ml of lysis
buffer, 3ml of low salt buffer (20mM Tris-Cl pH 8.0, 120mM
NaCl), 1ml of high salt buffer (20mMTris-Cl pH 8.0, 1MNaCl),
and finally with 3ml of low salt buffer. Peptides were eluted with
5ml of 10% acetic acid per ml column, diluted with 10ml of 0.1%
formic acid and purified by SPE (Oasis HLB, Waters) using 20
and 30% acetonitrile in 0.1% formic acid to elute the peptides.
For parallel reaction monitoring (PRM) analyses, the samples
were lyophilized and resuspended in buffer A. HLA-eluates were
injected together with a mix of 40 fmol of each heavy labeled
peptide. The Orbitrap Fusion LUMOS mass spectrometer
was operated in PRM-mode. Peptides KIGDFGLATE,
KIGDFGLATV, KIGDFGLATEK, and KIGDFGLATVK
were monitored. Selected peptides, the transitions and collision
energies can be found in Table S1. The isolation width of Q1
was 1.2 Da. MS2 resolution was 35,000 at an AGC target value
of 1 million at a maximum fill time of 100ms. The gradient was
run from 2 to 36% solvent B (20/80/0.1 water/acetonitrile/formic
acid (FA) v/v) in 120min. The nano-HPLC column was drawn
to a tip of ∼5µm and acted as the electrospray needle of the MS
source. PRM data analysis and data integration were performed
in Skyline 3.6.0.10493. Peptide abundances were calculated by
comparing the peak area of the eluted (light) and the peak area
of the spiked-in heavy peptides.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism version
8.0.1 and IBM SPSS Statistics version 25. Comparisons of
(sub)groups were performed with the Mann-Whitney U test for
continuous data and the Fisher exact test for categorical data. The
Cox proportional hazards model was used for univariate analysis.
Notably, log transformation of the widely differing CD8+ T
cell:CD1a+ LCH-cell ratios was performed to increase the
validity of the univariate analysis. Survival curves were estimated
with the Kaplan-Meier method and compared with the Log-rank
test. A p-value of <0.05 was considered statistically significant.
RESULTS
LCH-Cells Express Normal Levels of HLA
Class I and II Molecules at Their Cell
Surface
Since loss or downregulation of HLA expression has been shown
to be a major tumor escape mechanism from T lymphocytes
in a wide variety of cancers (63), we first evaluated by flow
cytometric analysis the levels of HLA class I and HLA-DR
expression on the surface of CD1a+ (LCH-)cells present in
n = 6 LCH-biopsies. The gating strategy applied is shown
in Figure S4. The mean fluorescent intensity (MFI) of HLA
class I and HLA-DR expression by CD1a+ (LCH-)cells was
comparable to MFI levels of HLA class I and HLA-DR expression
by CD1a− CD14+ (monocytic) cells present in the same
LCH-biopsies (Figure 1; HLA class I, p = 0.69; HLA-DR, p
= 0.94).
The HLA Genotype of LCH-Patients Does
Not Differ From Healthy Controls
Besides HLA expression, HLA subtype is a crucial factor
influencing whether a (neo)antigen is actually presented
at the surface of nucleated cells. Several earlier published
studies have suggested associations between particular
HLA subtypes and LCH disease (extension) (64–67). To
investigate this, we compared HLA genotype data from n
= 94 Dutch LCH-patients to the HLA genotypes of 5,604
healthy Dutch blood donors reflecting the HLA genotype of
the Dutch population (50). To maintain sufficient statistical
power, HLA genotype was compared at low resolution level.
No significant differences between Dutch LCH-patients and
the Dutch reference population were observed (Table S2).
Thus, our data do not support previous reports describing
excess frequency of HLA-Bw61 and HLA-Cw7 (64), HLA-B7
and HLA-DR2 (65), and HLA-DR4 and/or HLA-Cw7 (66)
genotypes in LCH-patients (Tables S2, S3). Moreover, our
results neither confirm that LCH-patients with unifocal bone
disease have significantly more often HLA-DR4 and/or HLA-
Cw7 (66) subtypes nor that patients with single-system LCH
have an increased prevalence of HLA-DRB1∗03 (67) when
compared to patients with multisystem LCH (Table S4 and
Figure S5, respectively).
BRAFV600E Mutation Correlates With
Decreased CD8+ T Cell Density in
LCH-Lesions
Assured that LCH-cells express HLA class I (and II) molecules
and that there is a normal HLA subtype distribution among
LCH-patients, we next investigated the presence of CD8+ T cells
in LCH-lesions. Various methods for the quantification of cell
numbers in (specific areas of) tissue sections exist, including
eyeball estimation, manual cell counting and automated digital
image analysis. Although automated digital image analysis
is increasingly being applied, manual cell counting is still
considered the golden standard (68). Accordingly, we first
determined the relative number of total CD3+ and CD3+CD8+
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FIGURE 1 | Flow cytometric measurements of HLA class I and HLA-DR
expression by LCH biopsy-derived hematopoietic cells. Mean Fluorescent
Intensity (MFI) of (A) HLA class I (W6/32) and (B) HLA-DR expression by live
CD1a+ (LCH-)cells, CD3+CD8− (T) cells and CD3+CD8+ (T) cells are depicted
relative to the MFI of HLA class I or HLA-DR expression by CD1a− CD14+
(monocytic) cells. The gating strategy applied is shown in Figure S4. The box
extends from the 25th to 75th percentiles. The line in the middle of the box is
plotted at the median. The whiskers go down to the smallest value and up to
the largest. Each individual value is plotted as a point superimposed on
the graph.
T cells in LCH-lesions using this method. Fluorescently stained
CD1a+, CD3+CD8− and CD3+CD8+ cells (Figure 2A) were
manually counted in LCH-biopsies from n = 101 patients
collected at first disease onset using the public ImageJ Cell
Counter plugin. A median of 1,810 cells (range: 188–9,301)
were counted in a median of 16 representative images (range:
2–56) taken at 400× magnification of tissue areas containing
phenotypically aberrant CD1a+ LCH-cells. Large inter- and
intrapatient heterogeneity was seen in the relative number of
LCH-lesional CD3+ and CD8+ T lymphocytes (Figure S6 and
Figure 2B, respectively). Calculated CD8+ T cell:CD1a+ LCH-
cell ratios (CD8 ratios) ranged from 0.00 to 4.96. The median
CD8 ratio was 0.06, corresponding to 1 CD8+ T cell per 16
CD1a+ LCH-cells. No significant difference in LCH-lesional
CD8 ratios was observed between bone and skin biopsies (p
= 0.37) nor between patients with single- or multisystem LCH
disease (p = 0.55). Yet, BRAFV600E mutated patients displayed
significantly lower LCH-lesional CD8 ratios when compared
to BRAF wildtype (BRAFWT) patients (p = 0.01; Figure 2C).
BRAFV600E mutated LCH-lesions had a median CD8 ratio of
0.0316, corresponding to 1 CD8+ T cell per 32 CD1a+ LCH-
cells. In contrast, BRAFWT lesions had a median CD8 ratio of
0.0775, corresponding to 1 CD8+ T cell per 13 CD1a+ LCH-
cells. BRAFV600E mutated lesions also had significantly lower
total CD3+ T cell:CD1a+ LCH-cell ratios than BRAFWT lesions
(p = 0.001; Figure S7). As manual selection of representative
tissue areas may introduce bias, we also analyzed whole slide
images taken from a subset of immunostained tissue sections
using a previously described semi-quantitative eyeball estimation
method (58, 59) (Figure S1) and a quantitative automated digital
image analysis method (Figure S2). The correlation between the
BRAFV600E mutation and decreased LCH-lesional CD3+ and
CD8+ T cell density was confirmed by these two additional
analysis methods (Figure S8).
Lesional CD8+ T Cell Density Does Not
Correlate With Event-Free Survival in LCH
We subsequently assessed whether lesional CD8+ T cell density
is of prognostic value in LCH. Using univariate cox regression
analysis, no significant association was observed between LCH-
lesional CD8 ratio and event-free survival (p = 0.46; Hazard
Ratio= 0.89; 95% Confidence Interval= 0.66–1.21). In addition,
no significant difference was present when patients were divided
by a median split, grouped in patients with HIGH or LOW CD8
ratios (Figure 2B and Table 1) and compared with regard to
event-free survival (p = 0.96, Figure 2D). Thus, LCH-lesional
CD8+ T cell density did not correlate with disease outcome in
this retrospective patient cohort.
The BRAFV600E Derived Neopeptide
KIGDFGLATEK Binds to HLA-A∗03:01 and
HLA-A∗11:01
To investigate the immunogenicity of the BRAFV600E mutation,
we used the online NetMHC 4.0 server (69) to explore
putative HLA class I binding 8–12 amino acid long (8–
12mer) neopeptides derived from the BRAFV600E protein. In
addition, NetCHOP 3.1 software (70) was used to predict
proteasomal cleavage motifs and thereby identify peptides that
are presumably generated by the human proteasome. From all
8–12mer BRAFV600E derived neopeptides that are generated
by the human proteasome according to NetCHOP, only a
single neopeptide, the 11mer KIGDFGLATEK, is predicted
to bind to one or more of the analyzed HLA class I
molecules (Table S5). According to NetMHC, KIGDFGLATEK
binds weakly to HLA-A∗11:01 and HLA-A∗03:01, expressed
by respectively n = 11/104 (11%) and n = 25/104 (24%)
LCH-patients from our cohort. The remainder of the 8–
12mer BRAFV600E derived neopeptides are all considered not be
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FIGURE 2 | LCH-lesional CD8+ T cell densities in first disease onset tissue biopsies of LCH-patients. (A) Representative images of immunostained phenotypically
aberrant CD1a+ LCH-cells (green), CD3+CD8− T cells (red), and CD3+CD8+ T cells (purple) that were manually counted. (B) Distribution of LCH-lesional CD8+ T
cell:CD1a+ LCH-cell ratios (CD8 ratios) in first-disease onset tissue biopsies of n = 101 LCH-patients. For Kaplan-Meier survival analysis (shown in D), patients were
divided by a median split and grouped in patients with HIGH or LOW CD8 ratios. (C) Distribution of CD8 ratios in BRAFV600E mutated (n = 48) and BRAF wildtype (n
= 45) LCH-lesions. (D) Kaplan-Meier survival analysis of patients with HIGH (n = 50) or LOW (n = 51) CD8 ratios. Event was defined as LCH disease progression or
reactivation. N, number of patients at risk.
generated by the human proteasome and/or to be non-binders.
Additional in vitro peptide-HLA binding studies however
demonstrated that KIGDFGLATEK binds with comparable
affinity to HLA-A∗11:01 as the strong binding reference peptide
(QVPLRPMTYK) that was used in our competition-based
peptide-HLA binding assay (60). In line with the predicted
binding affinity, this neopeptide was shown to also bind, albeit
less efficiently, to HLA-A∗03:01 (Table 2), as evidenced by the
small difference in nanomolar concentration that inhibited 50%
binding (IC50) of the fluorescently-labeled standard peptide
(KVFPCALINK) between KIGDFGLATEK and QVPLRPMTYK
(672 vs. 297 nM, respectively). Notably, NetMHCstab 1.0
software (71) predicts that the KIGDFGLATEK-HLA-A∗11:01
complex is highly stable (predicted half-life: 8.87 h) and that
the KIGDFGLATEK-HLA-A∗03:01 complex is weakly stable
(predicted half-life: 3.29 h). We also assessed the in vitro
HLA binding affinity of the 11mer KIGDFGLATVK and
10mer KIGDFGLATV BRAF wildtype peptides and of the
10mer KIGDFGLATE neopeptide (Table 2). In accordance
with the predictions made by NetMHC, KIGDFGLATVK was
shown to bind with comparable affinity to HLA-A∗11:01
as the strong binding reference peptide QVPLRPMTYK,
and to confer weaker binding to HLA-A∗03:01, just like
KIGDFGLATEK. Moreover, the 10mer BRAF wildtype peptide
KIGDFGLATV was shown to bind with comparable affinity
to HLA-A∗02:01 as the strong binding reference peptide
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TABLE 1 | Characteristics of LCH-patients from whom biopsies were analyzed for
LCH-lesional CD8+ T cell density.
All patients High LCH-
lesional CD8
ratio
Low LCH-
lesional CD8
ratio
P-value
Patients 101 50 (50%) 51 (50%)
Gender
Male 53 (52%) 29 (58%) 24 (47%) 0.32
Female 48 (48%) 21 (42%) 27 (53%)
Age
distribution
Pediatric
patients
85 (84%) 40 (80%) 45 (88%) 0.29
Adult patients 16 (16%) 10 (10%) 6 (12%)
Disease
extension
SS 78 (77%) 39 (78%) 39 (76%) 1
MS RO– 12 (12%) 5 (10%) 7 (14%) 0.76
MS RO+ 11 (11%) 6 (12%) 5 (10%) 0.76
Mutation
status
BRAFV600E
positive
48 (48%) 18 (36%) 30 (59%) 0.02
BRAFV600E
negative
45 (45%) 28 (56%) 17 (33%)
Unknown 8 (8%) 4 (8%) 4 (8%)
Chemotherapy
for FDO
34 (34%) 15 (30%) 19 (37%) 0.53
Follow-up
(median)
10.1 years 8.5 years 11.3 years 0.36
SS, single-system LCH disease; MS RO–, multisystem LCH disease without risk organ
(bone marrow, liver and/or spleen) involvement; MS RO+, multisystem LCH disease
with risk organ involvement; FDO, first disease onset; CD8 ratio, CD8+ T cell:CD1a+
LCH-cell ratio.
(FLPSDFFPSV) used in our assay. In contrast, its mutant
counterpart KIGDFGLATE does not bind at all to this particular
HLA class I molecule.
HLA-A∗11:01 and/or HLA-A∗03:01
Genotype Is Not Associated With
Increased Event-Free Survival in
BRAFV600E Mutated LCH-Patients
Having established that the BRAFV600E derived neopeptide
KIGDFGLATEK can bind to two HLA class I molecules that
are relatively frequent in the Caucasian population, we evaluated
whether BRAFV600E mutated LCH-patients expressing HLA-
A∗03:01 and/or HLA-A∗11:01 had increased event-free survival
as compared to LCH-patients without these HLA genotypes.
High-resolution HLA genotype data was available for n =
48 BRAFV600E mutated LCH-patients. Patient characteristics
are shown in Table S6. No significant difference in event-
free survival was observed between BRAFV600E mutated LCH-
patients with and without HLA-A∗03:01 and/or HLA-A∗11:01 (p
= 0.32, Figure S9).
KIGDFGLATEK Is Not Detected in the HLA
Class I Peptidome of BRAFV600E
Expressing Cells
To assess whether KIGDFGLATEK is actually presented on
the surface of cells that express BRAFV600E and HLA-A∗03:01
and/or HLA-A∗11:01, we performed mass spectrometry-based
targeted peptidomics of HLA class I presented peptides isolated
from various EBV-LCL transduced with a LZRS-retroviral vector
containing full length BRAFV600E protein and reporter Green
Fluorescent Protein (GFP) encoding DNA sequences. Based
on the results of the in silico analysis and in vitro peptide-
HLA binding assays, three different EBV-LCL were selected
for the transduction experiments with HLA-A∗03:01/HLA-
A∗02:01 (SB), HLA-A∗11:01/HLA-A∗02:01 (MLA), and HLA-
A∗02:01/HLA-A∗02:01 (JY) genotypes. ExtendedHLA genotypes
are shown in Table S7. After retroviral transduction, GFPhigh
cells were sorted and expanded in bulk. JY and MLA cell
lines that were mock transduced with a control (empty-)GFP
retroviral vector were analyzed in parallel. Flow cytometric
analysis demonstrated that neither retroviral transduction with
the BRAFV600E containing vector (Figure S10) nor transduction
with the control empty vector (data not shown) altered
HLA class I (W6/32) and HLA-DR expression at the cell
surface. Moreover, HLA subtype-specific antibodies (kindly
provided by Dr. D.L. Roelen, HLA genotyping laboratory
LUMC, Leiden) confirmed normal HLA subtype expression
by BRAFV600E transduced SB, MLA (Figure S10) and JY cells
(data not shown). We also included an HLA-A∗01/HLA-A∗24
bearing BRAFV600E mutated colon carcinoma cell line (HT29)
with earlier confirmed HLA (72–74) and BRAFV600E protein
(75, 76) expression in our analysis. Using parallel reaction
monitoring (PRM)-based targeted peptidomics (77), the 11mer
neopeptide KIGDFGLATEK was not detected in the HLA class I
peptidomes of both BRAFV600E expressing cell lines expressing
HLA-A∗03:01 or HLA-A∗11:01 (Table 3). Notably, neither the
11mer BRAF wildtype peptide KIGDFGLATVK was detected
in HLA class I peptides isolated from the mock or BRAFV600E
transduced SB and MLA EBV-LCL. In contrast, the 10mer
BRAF wildtype peptide KIGDFGLATV was detected in the HLA
class I peptidomes of 3/3 BRAFV600E transduced and 2/2 mock
transduced cell lines expressing HLA-A∗02:01 (Table 3).
DISCUSSION
A large number of studies have demonstrated a positive
association between overall CD8+ T cell density in the tumor
infiltrate and a favorable clinical prognosis in many different
types of cancers (6). In this study, we did not observe such
an association in a substantial cohort of LCH-patients with
well-documented clinical outcome. This dissimilarity between
LCH and other neoplastic disorders may be due to their
vast differences in mutational load and, correspondingly, the
number of T cell activating neoantigens that can arise from
this mutational burden. Furthermore, the immune suppressive
microenvironment in LCH-lesions (5, 14, 15, 18, 78–81)
may hamper CD8+ T cell infiltration (non-mutated), antigen
recognition and cytolytic function .
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TABLE 2 | In silico and in vitro HLA class I binding affinities of BRAFV600E and BRAF wildtype protein-derived peptides and two strong binding reference peptides.
Peptide Predicted
proteasomal
cleavage
Predicted HLA binding affinity (IC50, nM) In vitro HLA binding affinity (IC50, nM) 500 nM
NetMHC 3.4 NetMHC 4.0 Peptide-HLA binding assay
NetCHOP 3.1 A*02:01 A*03:01 A*11:01 A*02:01 A*03:01 A*11:01 A*02:01 A*03:01 A*11:01
KIGDFGLATV YES 38 17,310 23,823 107 13,515 19,725 40 NT NT 50 nM
KIGDFGLATE NO 15,997 20,112 23,609 19,485 22,113 23,743 86918 NT NT
KIGDFGLATVK YES 25,719 448 163 3,347 191 363 NT 415 32
KIGDFGLATEK YES 23,298 622 98 29,947 278 345 NT 672 45
QVPLRPMTYK NR 31,545 77 62 32,523 21 37 NT 297 36
FLPSDFFPSV NR 4 24,267 27,281 4 19,261 22,553 8 NT NT 0 nM
IC50, the concentration that inhibits 50% binding of a fluorescently-labeled standard peptide; nM, nanomolar; NR, not relevant, because these are the strong binding reference peptides;
NT, not tested. The color values correspond to the IC50 values 0–500 nM (0 dark red, 500 white).
TABLE 3 | Peptides detected using mass-spectrometry based targeted peptidomics of HLA class I peptides isolated from multiple BRAF wildtype or BRAFV600E
expressing cell lines.
Peptide Cell line
JY
mock
JY
BRAFV600E
MLA
mock
MLA
BRAFV600E
SB
BRAFV600E
HT29
1,900 × 10e6* 51 × 10e6 158 × 10e6 170 × 10e6 28 × 10e6 1,800 × 10e6
A*02:01 A*02:01 A*02:01 A*02:01 A*02:01 A*11:01 A*02:01 A*11:01 A*02:01 A*03:01 A*01 A*24
KIGDFGLATV + + + + + –
KIGDFGLATE – – – – – –
KIGDFGLATVK – – – – – –
KIGDFGLATEK – – – – – –
Mock, transduced with a control (empty-) GFP retroviral vector; BRAFV600E , transduced with a BRAFV600E -GFP retroviral vector; HT29, colon carcinoma cell line harboring the
heterozygous BRAFV600E mutation; +, peptide detected; –, peptide not detected; *, number of cells analyzed.
In line with an earlier undetailed observation (7), the
relative number of LCH-lesional CD8+ T cells appears low
in this study. Moreover, we demonstrate with three separate
analysis methods that BRAFV600E mutated LCH-patients display
lower lesional CD3+ and CD8+ T cell densities than BRAF
wildtype patients. Although the clinical significance of this latter
observation is not immediately apparent, it does point out that
the different MAPK pathway mutations expressed by neoplastic
LCH-cells seem to have a distinct impact on their immune
microenvironment. A number of studies on BRAFV600E positive
melanoma have already suggested that the BRAFV600E mutation
promotes immune evasion by upregulating the transcription of
many immunomodulatory chemokine and cytokine genes as
well as the internalization of cell surface HLA class I molecules
(82, 83). The presence of many of these immunomodulatory
chemokines and cytokines in LCH-lesions has been extensively
demonstrated (2). Notably, we did however observe normal HLA
class I expression by CD1a+ (LCH-)cells in two BRAFV600E
positive LCH-biopsies analyzed by flow cytometry (Figure 1A),
and showed that transduction of EBV-immortalized B cells
with a BRAFV600E encoding retroviral vector does not impair
HLA class I expression. Zeng and colleagues recently described
that BRAFV600E mutated LCH-patients have significantly higher
numbers of lesional Foxp3+ regulatory T cells and increased
PD-L1 expression by LCH-cells when compared to BRAFWT
patients (80). In accordance with this study, a preliminary
report by Chakraborty and others also describes that BRAFV600E
expressing LCH-cells display higher expression levels of ligands
for inhibitory receptors, including PD-L1/L2 and Galectin-9,
when compared to BRAFWT patients (19). Notably, the presence
of PD-1 expressing T cells in LCH-lesions has been reported
as well (18, 19), and was confirmed in (BRAFV600E positive)
patients from our cohort (Figure S11). PD-L1 blockade has
been shown to induce expansion of tumor-infiltrating CD8+
T cells (84). Thus, the reported increased PD-L1 expression
by BRAFV600E positive LCH-cells (19, 80) could explain the
decreased LCH-lesional CD8+ T cell density in BRAFV600E
mutated patients from our study. In addition, the immune
suppressive microenvironment in LCH-lesions (5, 14, 15, 18, 78–
81) may clarify why the rare CD8+ T cells that did make it
into these lesions had no significant clinical impact. This is
supported by our own observation of low numbers of HLA-
DRpos LCH-lesional CD8+ T cells (Figure 1), low numbers
of “licensed-to-kill” CD8+ T cells co-expressing the cytolytic
enzymes Perforin and Granzyme B (85) (Figure S12), and rare
presence of Caspase 3 expressing LCH-cells (data not shown).
HLA-DR is widely recognized as a marker of T cell activation
(86), and Caspase 3 is the hallmark marker of efficient target cell
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apoptosis induced by activated CD8+ T cells (87). In line with the
recently reported defective response of LCH-lesion infiltrating T
cells to allogeneic stimulation (19), these observations collectively
suggest that CD8+ T cells in LCH-lesions are often dysfunctional.
Future studies using (imaging) mass cytometry, which allows
the simultaneous detection of a multitude of cellular markers
(with spatial context), are needed to study the phenotypic
characteristics of LCH-lesional (CD8+) T cells in more detail.
Moreover, the alleged distinct impact of the different MAPK
pathway mutations on the immune microenvironment of
neoplastic LCH-cells should ideally be investigated in a LCH
mouse model.
Encouraged by published results suggesting that BRAFV600E
protein-derived neopeptides can trigger antitumor immunity
(41, 82), we used the most recent version of publicly
accessible NetMHC software to explore putatively HLA
class I binding neoantigens derived from the BRAFV600E
protein. Surprisingly, from all 8–12mer BRAFV600E derived
neopeptides that are predicted to be generated by the human
proteasome by NetCHOP 3.1 software, only a single neopeptide
(KIGDFGLATEK) was predicted to bind to one or more of
the analyzed HLA class I molecules. In vitro peptide-HLA
binding assays confirmed the predicted binding capacity of
KIGDFGLATEK to HLA-A∗03:01 and HLA-11∗01. In contrast
to the results generated with an earlier version of Syphpeiti
software (41), the NetMHC 4.0 server did not qualify the two
(putatively HLA-A∗02:01 binding) neopeptides LATEKSRWSG
and LATEKSRWS to beHLA-binders. Using PRM-based targeted
peptidomics, KIGDFGLATEK was not detected in the HLA class
I peptidomes of 2/2 BRAFV600E expressing EBV-LCL (MLA
BRAFV600E and SB BRAFV600E) that expressed normal levels of
HLA-A∗03:01 or HLA-A∗11:01. In contrast, the HLA-A∗02:01
binding BRAF wildtype peptide KIGDFGLATV was traceable in
HLA class I peptides isolated from 5/5 cell lines expressing this
HLA subtype, verifying normal antigen processing in these cells
and adequate sensitivity of our peptidomics approach. Since the
11mer BRAF wildtype peptide KIGDFGLATVKwas not detected
in mock (empty-GFP) nor BRAFV600E transduced EBV-LCL
as well, the apparent lack of KIGDFGLATEK presentation at
the cell surface seems not due to a competitive HLA binding
disadvantage relative to its wildtype counterpart (88). Instead,
both KIGDFGLATEK and KIGDFGLATVK peptides may
not be generated by the human proteasome. This could be
explained by the fact that both HLA-A∗03:01 and HLA-A∗11:01
molecules exclusively bind peptides with lysine as the C-terminal
anchor residue (89). NetCHOP software only produces neural
network predictions for proteosomal cleavage. Protein cleavage
yielding C-terminal lysine residues is, however, not readily
accomplished by the human proteasomes alone. Instead, this
process requires the cytosolic endopeptidases nardilysin and
thimet oligopeptidase as well (89, 90). Another possibility is that
the 11mer KIGDFGLATVK and KIGDFGLATEK peptides are
expressed at the cell surface, but that they are underrepresented
among the large pool of naturally presented ligands eluted from
peptide-HLA class I complexes, because of a common peptide
length distribution including mostly 9mer peptides and far less
8mer, 10mer, and longer peptides (91). This is also demonstrated
by the list of peptides that were detected using data-dependent
acquisition-based peptidomics in the HLA class I peptide pools
isolated from the mock transduced JY and MLA EBV-LCL
(Table S8). The high sensitivity of targeted peptidomics makes
this option however less probable, although it must be noted that
lower numbers (28–170 × 10e6) of BRAFV600E transduced SB,
MLA, and JY B cells were subjected to analysis as compared to
mock transduced B cells (158–1,900 × 10e6). This was because
GFPhigh BRAFV600E transduced cells displayed intrinsically
higher apoptosis rates leading to substantially lower yields (data
not shown).
In addition to the importance of CD8+ T cells, multiple
studies have highlighted the importance of CD4+ T cells in tumor
rejection (34, 92–96). Notably, one study identified BRAFV600E-
specific CD4+ T cells after repetitive peptide stimulation of
peripheral blood mononuclear cells from three melanoma
patients whose metastatic tumors harbored the BRAFV600E
mutation (40). Moreover, Veatch and colleagues recently
identified HLA-DQB1∗03-restricted BRAFV600E-specific CD4+
T cells in an acral melanoma patient, who nonetheless developed
metastases under ipilimumab (anti-CTLA-4) immunotherapy
(97). Unfortunately, the precise amino acid sequence of the
recognized neoantigen was not reported. Available software tools
to predict HLA class II binding peptides are known to be
significantly less accurate than available algorithms for predicting
HLA class I binding peptides. Moreover, the yield of BRAFV600E
transduced B cells expressing HLA-DQB1∗03:02 (SB EBV-LCL)
was far too small to elute sufficient quantities of peptide-
HLA class II complexes needed for successful data-dependent
acquisition-based peptidomics. We could, therefore, not confirm
that this recently identified BRAFV600E protein-derived HLA-
DQB1∗03 binding neopeptide is naturally processed and
presented at the cell surface of our BRAFV600E transduced HLA-
DQB1∗03 expressing EBV-LCL. We did however investigate
whether BRAFV600E mutated LCH-patients expressing HLA-
DQB1∗03 in general, or HLA-DQB1∗03:02 and/or HLA-
DQB1∗03:03 in particular [due to their putative strongest binding
and/or peptide-HLA complex stability (97)], had increased
event-free survival when compared to BRAFV600E mutated
patients without these HLA genotypes. Notably, HLA class I
subtype has already been demonstrated to influence response
to checkpoint blockade immunotherapy in patients with diverse
cancers (98). Neither BRAFV600E mutated LCH-patients with
HLA-DQB1∗03 (n = 30, 62.5%) nor with HLA-DQB1∗03:02
and/or HLA-DQB1∗03:03 (n = 18, 37.5%) displayed increased
event-free survival when compared to patients without these
HLA alleles (p = 0.78 and p = 0.57, respectively; data not
shown). Thus, although we agree that adoptive cell therapy with
T cell receptor-engineered BRAFV600E-specific CD4+ T cells may
offer great therapeutic potential, the clinical impact of potentially
present BRAFV600E-specific CD4+ T cells in HLA-DQB1∗03
bearing, BRAFV600E mutated LCH-patients is questionable. Of
note, the rare CD4+ BRAFV600E-specific T cells reported in the
acral melanoma patient by Veatch et al. were not paralleled
by BRAFV600E-specific CD8+ T cells, but by diverse CD8+
T cells reactive to multiple melanoma-associated self-antigens.
Whether such non-mutated tumor-associated antigens are also
expressed by LCH-cells is of great interest and remains to
be determined. This will however be challenging given the
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(relatively) low numbers of neoplastic LCH-cells that can be
obtained for peptidome analysis from fresh or frozen LCH tissue
samples, which are in addition very scarce due to the rarity of
the disease.
Since the generation of neoantigens is a probabilistic process
(47), we can of course not rule out that other somatic
mutations in LCH-cells are a source of neoantigens that are
naturally processed and presented in (stable) peptide-HLA
class I complexes. Based on recent insights, this probability is
however very low. With the development of deep-sequencing
technologies, comprehensive analyses of neoantigen-specific T
cell responses have been carried out for a substantial number of
cancer patients since 2013 (25, 26, 29). The striking conclusion
that can now be drawn from these studies is that only a very small
fraction of non-synonymous mutations leads to the formation
of a neoantigen for which CD4+ or CD8+ T cell reactivity
can be detected (25). Most melanomas and a sizable fraction
of other high-prevalence cancers in adults have a mutational
load above 10 somatic mutations per Mb, corresponding to
∼150 non-synonymous mutations within expressed genes (25,
99, 100). Even in melanoma patients, neoantigen-specific T cell
reactivity is however not always observed (95). Thus, there
is a growing awareness that tumor types with a mutational
load below 10, and especially below 1 mutation(s) per Mb, are
less likely to express neoantigens that can be recognized by
autologous T cells (25). Although the total number of LCH
samples analyzed by whole-exome sequencing (WES) is still small
(101), a remarkably low frequency of somatic mutations in LCH-
cells was found in the largest WES analysis to date (n = 41),
with a median of 1 somatic mutation per patient (0.03 mutations
per Mb) (22). Thus, the likelihood of neoantigen formation
and concurrent induction of protective neoantigen-specific T
cell responses in LCH-patients seems very low (25). Notably,
Goyal and others recently demonstrated a lowmutational burden
in other histiocytic neoplasms as well (102). We therefore
question the usefulness of classical immune checkpoint inhibitors
for the treatment of relapsed or refractory LCH (or other
histiocytic neoplasms), especially given that these LCH-patients
often bear the BRAFV600E mutation (44), and that pretherapy
intratumoral CD8+ T cell density has been shown to positively
correlate with mutational burden, neoantigen load and response
to immune checkpoint inhibition in many other neoplastic
diseases (103, 104).
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